Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing
Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing
Body unavailable. Use the original source.
Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.